These results are consistent with a more extensive study in mice with an intravenous CCR2-depleting antibody injection, which showed that depletion of CCR2+ monocytes in a therapeutic tumor setting leads to reduced tumor growth, demonstrating their immunosuppressive capacity. This evidence concerns the gene CCR2 and neoplasm.